BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14502757)

  • 1. New cyanopeptide-derived low molecular weight thrombin inhibitors.
    Radau G; Gebel J; Rauh D
    Arch Pharm (Weinheim); 2003 Aug; 336(8):372-80. PubMed ID: 14502757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New cyanopeptide-derived low molecular weight inhibitors of trypsin-like serine proteases.
    Radau G; Schermuly S; Fritsche A
    Arch Pharm (Weinheim); 2003 Aug; 336(6-7):300-9. PubMed ID: 12953218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyanopeptide analogues: new lead structures for the design and synthesis of new thrombin inhibitors.
    Radau G; Stürzebecher J
    Pharmazie; 2002 Nov; 57(11):729-32. PubMed ID: 12611274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and X-ray crystal structures of human thrombin with synthetic cyanopeptide-analogues.
    Radau G; Fokkens J
    Pharmazie; 2007 Feb; 62(2):83-8. PubMed ID: 17341023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
    Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.
    Wang G; Goyal N; Hopkinson B
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3798-803. PubMed ID: 19447619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.
    De Simone G; Menchise V; Omaggio S; Pedone C; Scozzafava A; Supuran CT
    Biochemistry; 2003 Aug; 42(30):9013-21. PubMed ID: 12885234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
    Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors.
    Lee L; Kreutter KD; Pan W; Crysler C; Spurlino J; Player MR; Tomczuk B; Lu T
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6266-9. PubMed ID: 17889527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxyguanidines. Part 2: Discovery of a novel orally active thrombin inhibitor through structure-based drug design and parallel synthesis.
    Lu T; Markotan T; Coppo F; Tomczuk B; Crysler C; Eisennagel S; Spurlino J; Gremminger L; Soll RM; Giardino EC; Bone R
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3727-31. PubMed ID: 15203151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of graftable thrombin inhibitors for the preparation of blood-compatible polymer materials.
    Salvagnini C; Michaux C; Remiche J; Wouters J; Charlier P; Marchand-Brynaert J
    Org Biomol Chem; 2005 Dec; 3(23):4209-20. PubMed ID: 16294249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efforts toward oral bioavailability in factor VIIa inhibitors.
    Vijaykumar D; Rai R; Shaghafi M; Ton T; Torkelson S; Leahy EM; Riggs JR; Hu H; Sprengeler PA; Shrader WD; O'Bryan C; Cabuslay R; Sanford E; Gjerstadt E; Liu L; Sukbuntherng J; Young WB
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3829-32. PubMed ID: 16650987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Evaluation of Spumigin Analogues Library with Thrombin Inhibitory Activity.
    Žula A; Będziak I; Kikelj D; Ilaš J
    Mar Drugs; 2018 Oct; 16(11):. PubMed ID: 30373260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of a small library of graftable thrombin inhibitors derived from (L)-arginine.
    Salvagnini C; Gharbi S; Boxus T; Marchand-Brynaert J
    Eur J Med Chem; 2007 Jan; 42(1):37-53. PubMed ID: 17010480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motif.
    Kreutter KD; Lu T; Lee L; Giardino EC; Patel S; Huang H; Xu G; Fitzgerald M; Haertlein BJ; Mohan V; Crysler C; Eisennagel S; Dasgupta M; McMillan M; Spurlino JC; Huebert ND; Maryanoff BE; Tomczuk BE; Damiano BP; Player MR
    Bioorg Med Chem Lett; 2008 May; 18(9):2865-70. PubMed ID: 18420408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and characterization of dipetacompinR10H, a dipetalogastin II-derived, classical competitive thrombin inhibitor.
    Bitter T; López M; Nowak G
    Thromb Haemost; 2007 Jan; 97(1):139-45. PubMed ID: 17200781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
    Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.